New frontiers in immune checkpoint B7-H3 (CD276) research and drug development
Abstract B7-H3 (CD276), a member of the B7 family of proteins, is a key player in cancer progression. This immune checkpoint molecule is selectively expressed in both tumor cells and immune cells within the tumor microenvironment. In addition to its immune checkpoint function, B7-H3 has been linked...
Main Authors: | Ayechew Adera Getu, Abiye Tigabu, Ming Zhou, Jianrong Lu, Øystein Fodstad, Ming Tan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-03-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12943-023-01751-9 |
Similar Items
-
CD276 as a Candidate Target for Immunotherapy in Medullary Thyroid Cancer
by: Kinga Hińcza-Nowak, et al.
Published: (2023-06-01) -
B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
by: Umberto Malapelle, et al.
Published: (2022-12-01) -
Progress on the pathological roles of immune checkpoint CD276 protein in tumorigenesis and development
by: CHEN Zhongjie, HUANG Jiaru, HU Qing, ZHAO Zhenqin, CHEN Qiaoqiao, SUN Junyuan, JIA Jing
Published: (2023-07-01) -
B7-H3/CD276 and small-cell lung cancer: What's new?
by: Federico Pio Fabrizio, et al.
Published: (2024-01-01) -
CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models
by: Andrea Timpanaro, et al.
Published: (2023-11-01)